Shares of MedPal AI PLC plunged 7.1% to £5.58 on September 21, 2026, after the London-listed health-technology company announced a fresh issue of equity alongside a trading update — a combination that spooked investors already navigating a volatile week for the stock. MedPal AI Raises Another £5 Million by Selling New Shares at a Steep Discount — Can Breakneck Revenue Growth Justify the Constant Dilution?
Shares tumbled as MedPal AI PLC disclosed yet another equity raise on September 21, flooding the market with 100 million new shares priced at a 17% discount to the previous close — the company's third major fundraise in five months. The stock dropped 7.1% to 5.58p, and for investors who have watched the share count balloon all year, the question is whether the company's explosive revenue trajectory can outrun the relentless creation of new stock.
£5 Million at 5p Per Share Means Existing Owners Get Squeezed
MedPal raised gross proceeds of £5 million through the issue of 100,000,000 new ordinary shares at 5.0 pence each.
That placing price represents a roughly 17% discount to the 6.0p closing price on September 18. For shareholders who bought at £6p or higher in recent weeks, the new shares are immediately underwater relative to their cost — a bitter pill. The company's broker, CREST, also received warrants over another 6 million shares at the same price , adding future dilution on top of today's hit.
Revenue Is Growing Fast — But So Is the Fundraising Habit
MedPal says its annualised revenue run rate — the current monthly pace projected over 12 months — has reached over £35 million, up from £28 million reported for August and just £8.6 million in July. That is a staggering trajectory. But context matters: in July 2026 the company raised £5 million at 3.5p per share , and before that it raised £5 million in a prior round, and £3 million in April 2026. Each round diluted holders, and the share count now sits near 883 million after today's issue. Revenue growth is real, but it's being fueled by continuous cash injections.
The Numbers Still Show Deep Losses
As of mid-2026, MedPal carried a market capitalisation of roughly £24 million, trailing twelve-month revenue of just £1.6 million, and net losses of -£7.1 million. The company's return on equity was a staggering -4,338%, signalling it is burning capital far faster than it earns. Until quarterly filings catch up with the claimed £35 million run rate, skeptics have ample reason to doubt the math.
Existing Shareholders Backed the Deal — But That Cuts Both Ways
The placing was predominantly taken up by existing shareholders, along with institutional and other investors. Management will spin that as a vote of confidence. The alternative read: insiders had to step in because outside demand at a 17% discount was not enough on its own. The next earnings report, due October 28, will be the first real test of whether booked revenue matches the headline run rate — and whether this cash raise buys enough runway to reach profitability.